Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential

Yangbo Feng, Philip V. Lograsso, Olivier Defert, Rongshi Li

Research output: Contribution to journalReview article

98 Citations (Scopus)

Abstract

Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates. As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathological conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis. To date, two ROCK inhibitors have been approved for clinical use in Japan (fasudil and ripasudil) and one in China (fasudil). In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014. In this Perspective, we present a comprehensive review of the physiological and biological functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.

Original languageEnglish (US)
Pages (from-to)2269-2300
Number of pages32
JournalJournal of Medicinal Chemistry
Volume59
Issue number6
DOIs
StatePublished - Mar 24 2016

Fingerprint

rho-Associated Kinases
Glaucoma
Intracranial Vasospasm
Erectile Dysfunction
Threonine
Serine
Osteoporosis
Renal Insufficiency
Insulin Resistance
China
Japan
Therapeutics
Asthma
fasudil
Neoplasms
K-115

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. / Feng, Yangbo; Lograsso, Philip V.; Defert, Olivier; Li, Rongshi.

In: Journal of Medicinal Chemistry, Vol. 59, No. 6, 24.03.2016, p. 2269-2300.

Research output: Contribution to journalReview article

Feng, Yangbo ; Lograsso, Philip V. ; Defert, Olivier ; Li, Rongshi. / Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 6. pp. 2269-2300.
@article{3dbfc46f2e6440629026ab17038e4f19,
title = "Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential",
abstract = "Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates. As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathological conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis. To date, two ROCK inhibitors have been approved for clinical use in Japan (fasudil and ripasudil) and one in China (fasudil). In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014. In this Perspective, we present a comprehensive review of the physiological and biological functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.",
author = "Yangbo Feng and Lograsso, {Philip V.} and Olivier Defert and Rongshi Li",
year = "2016",
month = "3",
day = "24",
doi = "10.1021/acs.jmedchem.5b00683",
language = "English (US)",
volume = "59",
pages = "2269--2300",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential

AU - Feng, Yangbo

AU - Lograsso, Philip V.

AU - Defert, Olivier

AU - Li, Rongshi

PY - 2016/3/24

Y1 - 2016/3/24

N2 - Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates. As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathological conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis. To date, two ROCK inhibitors have been approved for clinical use in Japan (fasudil and ripasudil) and one in China (fasudil). In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014. In this Perspective, we present a comprehensive review of the physiological and biological functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.

AB - Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates. As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathological conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis. To date, two ROCK inhibitors have been approved for clinical use in Japan (fasudil and ripasudil) and one in China (fasudil). In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014. In this Perspective, we present a comprehensive review of the physiological and biological functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.

UR - http://www.scopus.com/inward/record.url?scp=84962193209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962193209&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b00683

DO - 10.1021/acs.jmedchem.5b00683

M3 - Review article

C2 - 26486225

AN - SCOPUS:84962193209

VL - 59

SP - 2269

EP - 2300

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -